Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases.
Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases.
复制标题
DOI：
10.3892/etm.2018.6109
复制
发表时间：
2018-06
影响因子：
2.7
通讯作者：
Z. Lv;Min Liu;Jinghui Shen;D. Xiang;Yunfeng Ma;Yanhong Ji
中科院分区：
文献类型：
--
作者：
Z. Lv;Min Liu;Jinghui Shen;D. Xiang;Yunfeng Ma;Yanhong Ji
白细胞介素-10（IL-10）、白细胞介素-17 A（IL-17 A）和转化生长因子α（TGF-α）与乳腺癌的进展有关。然而，这些细胞因子在导管癌中的诊断和预后作用仍不清楚。本研究旨在检测乳腺良、恶性疾病患者血清中IL-10、IL-17和TGF-α的水平，并探讨其在乳腺导管癌中的临床意义。从378例乳腺疾病患者和70例健康受试者中收集术前血清样本。采用ELISA法检测IL-10、IL-17 A和TGF-α水平。评价不同乳腺疾病患者血清中这些细胞因子的水平。此外，这些细胞因子的水平和雌激素受体（ER），孕激素受体（PR）和人表皮生长因子受体2（HER 2）在导管癌的表达之间的相关性进行了测定。结果表明，乳腺导管癌和乳腺不典型增生患者血清IL-10和IL-17 A水平明显升高。此外，IL-10和IL-17 A水平在临床肿瘤分期更严重的患者和ER-和PR-肿瘤中升高。此外，高血清TGF-α水平与HER 2+肿瘤相关。TGF-α和IL-17 A水平之间存在强正相关。因此，本研究的结果显示，血清IL-10、IL-17 A和TGF-α水平升高与导管癌密切相关，特别是与肿瘤分期密切相关。乳腺导管癌组织中IL-10、IL-17 A水平升高与ER、PR阴性表达相关，TGF-α水平升高与HER 2阳性表达相关。因此，可以测量血清细胞因子水平以鉴定具有不良预后的患者，其可以从更积极的管理和治疗中受益。
Interleukin-10 (IL-10), interleukin-17A (IL-17A) and transforming growth factor α (TGF-α) have been implicated in the progression of breast cancer. However, the diagnostic and prognostic roles of these cytokines in ductal carcinoma remain unclear. The present study therefore aimed to determine the serum levels of IL-10, IL-17 and TGF-α in subjects with benign and malignant breast diseases and to evaluate the clinical significance of these cytokines in ductal carcinoma. Pre-operative serum samples were collected from 378 patients with breast disease and 70 healthy subjects. IL-10, IL-17A and TGF-α levels were measured using ELISA. Serum levels of these cytokine in patients with different breast diseases were evaluated. Furthermore, correlations between levels of these cytokines and the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in ductal carcinoma were determined. The results demonstrated that serum levels of IL-10 and IL-17A were significantly increased in subjects with atypical hyperplasia and ductal carcinoma. Furthermore, IL-10 and IL-17A levels were increased in patients with a more serious clinical tumor stage and tumors that were ER- and PR-. Furthermore, high serum levels of TGF-α were associated with HER2+ tumors. A strong positive correlation was identified between TGF-α and IL-17A levels. Therefore, the results of the current study revealed that elevated serum IL-10, IL-17A and TGF-α levels are strongly associated with ductal carcinoma, specifically with tumor stage. High serum levels of IL-10 and IL-17A were also associated with the negative expression of ER and PR in ductal carcinoma, and high serum levels of TGF-α were associated with the positive expression of HER2 in ductal carcinoma. Thus, serum cytokine levels may be measured to identify patients with a poor prognosis who may benefit from more aggressive management and treatment.